Riping Wu1, Chunmei Shi1, Qiang Chen1,2, Fan Wu3, Qiaolian Li3. 1. Department of Medical Oncology, Fujian Medical University Union Hospital Fuzhou, Fujian Province, People's Republic of China. 2. Stem Cell Research Institute, Fujian Medical University Fuzhou, Fujian Province, People's Republic of China. 3. Fujian Medical University Fuzhou, Fujian Province, People's Republic of China.
Abstract
INTRODUCTION: Circulating tumor DNA (ctDNA) for monitoring the effects of chemotherapy and predicting prognosis in advanced gastric cancer have not been thoroughly investigated. METHODS: We performed next-generation sequencing (NGS) of ctDNA from 23 gastric cancer patients. Then the genetic information and clinical information were statistically analyzed. RESULTS: In this study, the frequency of TP53 was significantly different between the effective and ineffective groups (P = 0.040), and the number of TP53 mutations was more frequent in the ineffective group. Missense mutation was a significant difference between the treatment effect groups (P = 0.026). The number of gene mutations and the change in copy number levels were related to therapeutic effect. Among the ineffective group, there was a significant difference in the number of gene mutations (P = 0.0006). We further divided the number of gene mutations into an increase group and a decrease group, and found that there was a significant difference between the effective and ineffective groups (P = 0.038). Finally, it was found that patients with high mutation abundance of gastric cancer had a shorter overall survival than patients with low mutation abundance (P<0.05). CONCLUSION: ctDNA can be used as an effective tool to monitor the efficacy of chemotherapy and predict prognosis in advanced gastric cancer. IJCEP
INTRODUCTION: Circulating tumor DNA (ctDNA) for monitoring the effects of chemotherapy and predicting prognosis in advanced gastric cancer have not been thoroughly investigated. METHODS: We performed next-generation sequencing (NGS) of ctDNA from 23 gastric cancerpatients. Then the genetic information and clinical information were statistically analyzed. RESULTS: In this study, the frequency of TP53 was significantly different between the effective and ineffective groups (P = 0.040), and the number of TP53 mutations was more frequent in the ineffective group. Missense mutation was a significant difference between the treatment effect groups (P = 0.026). The number of gene mutations and the change in copy number levels were related to therapeutic effect. Among the ineffective group, there was a significant difference in the number of gene mutations (P = 0.0006). We further divided the number of gene mutations into an increase group and a decrease group, and found that there was a significant difference between the effective and ineffective groups (P = 0.038). Finally, it was found that patients with high mutation abundance of gastric cancer had a shorter overall survival than patients with low mutation abundance (P<0.05). CONCLUSION: ctDNA can be used as an effective tool to monitor the efficacy of chemotherapy and predict prognosis in advanced gastric cancer. IJCEP
Authors: J M Riedinger; J Wafflart; G Ricolleau; N Eche; H Larbre; J P Basuyau; I Dalifard; K Hacene; M F Pichon Journal: Ann Oncol Date: 2006-06-09 Impact factor: 32.976
Authors: S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks Journal: Science Date: 1994-11-04 Impact factor: 47.728
Authors: Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein Journal: Nature Date: 2012-06-28 Impact factor: 49.962
Authors: Ken Chen; John W Wallis; Michael D McLellan; David E Larson; Joelle M Kalicki; Craig S Pohl; Sean D McGrath; Michael C Wendl; Qunyuan Zhang; Devin P Locke; Xiaoqi Shi; Robert S Fulton; Timothy J Ley; Richard K Wilson; Li Ding; Elaine R Mardis Journal: Nat Methods Date: 2009-08-09 Impact factor: 28.547
Authors: Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz Journal: Nat Biotechnol Date: 2013-02-10 Impact factor: 54.908